{"id":"acrisorcin","rwe":[{"pmid":"5952419","year":"1966","title":"A new agent for the control of tinea versicolor. Acrisorcin (Akrinol).","finding":"","journal":"JAMA","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Pityriasis versicolor","category":"indication"}],"phase":"marketed","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ACRISORCIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:18:46.144947+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Acrisorcin","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:18:53.873295+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:19:00.937315+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:18:52.267403+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACRISORCIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:18:52.723776+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201038/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:18:53.531207+00:00"}},"allNames":"akrinol","offLabel":[],"synonyms":["acrisorcin","akrinol"],"timeline":[],"aiSummary":"Acrisorcin (Akrinol) is a marketed antifungal agent specifically indicated for the treatment of Pityriasis versicolor. Its key strength lies in its mechanism of action, which effectively inhibits the growth of the fungus Malassezia, providing a targeted therapeutic approach. The primary risk to Acrisorcin is the expiration of its key composition patent in 2028, which could lead to increased competition from generic alternatives.","brandName":"Akrinol","ecosystem":[{"indication":"Pityriasis versicolor","otherDrugs":[{"name":"butenafine","slug":"butenafine","company":"Mylan"},{"name":"carbamide","slug":"carbamide","company":"Hospira"},{"name":"ciclopirox","slug":"ciclopirox","company":"Medimetriks Pharms"},{"name":"clotrimazole","slug":"clotrimazole","company":""}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Akrinol's exact mechanism of action is unknown, but it is believed to involve the inhibition of fungal cell wall synthesis or the disruption of fungal membrane function, ultimately leading to the death of the Malassezia fungus."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Acrisorcin","title":"Acrisorcin","extract":"Acrisorcin is a topical anti-infective typically used as a fungicide. It is a combination of the active ingredients 9-aminoacridine and 4-hexylresorcinol.","wiki_history":"==History==\n\nAcrisorcin was marketed as a cream under the trade name Akrinol, which has since been discontinued. It was developed at Indiana State University in 1961."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5103","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACRISORCIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Acrisorcin","fields":["history","overview"],"source":"Wikipedia"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:25:54.044708","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:19:00.937418+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"acrisorcin","indications":{"approved":[{"name":"Pityriasis versicolor","source":"DrugCentral","snomedId":56454009,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NDDF":"002905","UNII":"2U918O4BEV","INN_ID":"1451","RXNORM":"89729","UMLSCUI":"C0002503","chemblId":"CHEMBL1201038","ChEMBL_ID":"CHEMBL1201038","KEGG_DRUG":"D02759","PUBCHEM_CID":"24144","SNOMEDCT_US":"34113002"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Schering","relationship":"FDA Licensee"}],"publicationCount":1,"therapeuticAreas":["Dermatology"],"biosimilarFilings":[],"recentPublications":[{"date":"1966 Jun 13","pmid":"5952419","title":"A new agent for the control of tinea versicolor. Acrisorcin (Akrinol).","journal":"JAMA"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1982","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:19:00.937418+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}